BR112012000750A8 - Sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo - Google Patents
Sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmoInfo
- Publication number
- BR112012000750A8 BR112012000750A8 BR112012000750A BR112012000750A BR112012000750A8 BR 112012000750 A8 BR112012000750 A8 BR 112012000750A8 BR 112012000750 A BR112012000750 A BR 112012000750A BR 112012000750 A BR112012000750 A BR 112012000750A BR 112012000750 A8 BR112012000750 A8 BR 112012000750A8
- Authority
- BR
- Brazil
- Prior art keywords
- salt
- citrate salt
- pharmaceutical composition
- composition including
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SAL CITRATO DE 9E-15-(2-PIRROLIDIN-1-IL-ETÓXI)-7,12,25-TRIOXA-19,21,24-TRIAZA-TETRACICLO[18.3.1.1(2,5).1(14,18)]-IEXACOSA-1(24),2, 4, 9,14,16,18(26),20,22-NONAENO. A presente invenção relaciona-se a certos sais de um 9E-15-(2-pirrolidin-1-il-etóxi)- 7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14, 18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno (Composto 1) que têm sido encontrados ter propriedades melhoradas. Em particular a presente invenção relaciona-se ao sal citrato deste composto. A invenção também se relaciona às composições farmacêuticas contendo o sal citrato e método de uso do sal citrato no tratamento de certas condições médicas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22560909P | 2009-07-15 | 2009-07-15 | |
| US61/225609 | 2009-07-15 | ||
| PCT/SG2010/000265 WO2011008172A1 (en) | 2009-07-15 | 2010-07-14 | 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012000750A2 BR112012000750A2 (pt) | 2016-08-09 |
| BR112012000750A8 true BR112012000750A8 (pt) | 2018-02-06 |
| BR112012000750B1 BR112012000750B1 (pt) | 2021-05-25 |
Family
ID=42790728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012000750-5A BR112012000750B1 (pt) | 2009-07-15 | 2010-07-14 | sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9062074B2 (pt) |
| EP (1) | EP2454266B1 (pt) |
| JP (2) | JP6013911B2 (pt) |
| CN (1) | CN102762577B (pt) |
| AR (2) | AR077483A1 (pt) |
| BR (1) | BR112012000750B1 (pt) |
| CA (1) | CA2768210C (pt) |
| DK (1) | DK2454266T3 (pt) |
| ES (1) | ES2429525T3 (pt) |
| HK (1) | HK1178159A1 (pt) |
| HR (1) | HRP20130941T1 (pt) |
| MX (1) | MX2012000680A (pt) |
| PL (1) | PL2454266T3 (pt) |
| PT (1) | PT2454266E (pt) |
| RU (1) | RU2543721C2 (pt) |
| SI (1) | SI2454266T1 (pt) |
| SM (1) | SMT201300112B (pt) |
| TW (1) | TWI537276B (pt) |
| WO (1) | WO2011008172A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113559075A (zh) | 2014-11-17 | 2021-10-29 | 康泰科思特生物制药公司 | 奥那司酮延长释放组合物和方法 |
| AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
| US10548905B2 (en) | 2015-12-15 | 2020-02-04 | Context Biopharma Inc. | Amorphous onapristone compositions and methods of making the same |
| US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY110603A (en) * | 1993-05-27 | 1998-08-29 | Novartis Ag | Tetrahydropyran derivatives |
| US7151096B2 (en) * | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| WO2007058628A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Heteroalkyl linked pyrimidine derivatives |
-
2010
- 2010-07-14 BR BR112012000750-5A patent/BR112012000750B1/pt active IP Right Grant
- 2010-07-14 WO PCT/SG2010/000265 patent/WO2011008172A1/en active Application Filing
- 2010-07-14 PL PL10737645T patent/PL2454266T3/pl unknown
- 2010-07-14 CN CN201080032627.5A patent/CN102762577B/zh active Active
- 2010-07-14 DK DK10737645.1T patent/DK2454266T3/da active
- 2010-07-14 EP EP10737645.1A patent/EP2454266B1/en active Active
- 2010-07-14 PT PT107376451T patent/PT2454266E/pt unknown
- 2010-07-14 CA CA2768210A patent/CA2768210C/en active Active
- 2010-07-14 SI SI201030347T patent/SI2454266T1/sl unknown
- 2010-07-14 JP JP2012520571A patent/JP6013911B2/ja active Active
- 2010-07-14 US US13/384,139 patent/US9062074B2/en active Active
- 2010-07-14 ES ES10737645T patent/ES2429525T3/es active Active
- 2010-07-14 RU RU2012105044/04A patent/RU2543721C2/ru active
- 2010-07-14 MX MX2012000680A patent/MX2012000680A/es active IP Right Grant
- 2010-07-15 AR ARP100102594A patent/AR077483A1/es not_active Application Discontinuation
- 2010-07-15 TW TW099123331A patent/TWI537276B/zh active
-
2013
- 2013-04-29 HK HK13105191.1A patent/HK1178159A1/xx unknown
- 2013-10-04 SM SM201300112T patent/SMT201300112B/xx unknown
- 2013-10-07 HR HRP20130941AT patent/HRP20130941T1/hr unknown
-
2015
- 2015-05-07 JP JP2015094972A patent/JP2015164941A/ja active Pending
-
2019
- 2019-08-05 AR ARP190102219A patent/AR114987A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2454266T3 (da) | 2013-09-08 |
| WO2011008172A1 (en) | 2011-01-20 |
| BR112012000750A2 (pt) | 2016-08-09 |
| SMT201300112B (it) | 2013-11-08 |
| US20120196876A1 (en) | 2012-08-02 |
| SI2454266T1 (sl) | 2013-10-30 |
| JP2012533539A (ja) | 2012-12-27 |
| MX2012000680A (es) | 2012-02-28 |
| JP2015164941A (ja) | 2015-09-17 |
| JP6013911B2 (ja) | 2016-10-25 |
| CA2768210C (en) | 2017-08-15 |
| ES2429525T3 (es) | 2013-11-15 |
| TWI537276B (zh) | 2016-06-11 |
| PT2454266E (pt) | 2013-10-10 |
| BR112012000750B1 (pt) | 2021-05-25 |
| AR077483A1 (es) | 2011-08-31 |
| US9062074B2 (en) | 2015-06-23 |
| RU2012105044A (ru) | 2013-08-20 |
| HK1178159A1 (en) | 2013-09-06 |
| CN102762577B (zh) | 2015-01-07 |
| TW201107336A (en) | 2011-03-01 |
| AR114987A2 (es) | 2020-11-11 |
| EP2454266A1 (en) | 2012-05-23 |
| EP2454266B1 (en) | 2013-07-10 |
| RU2543721C2 (ru) | 2015-03-10 |
| CN102762577A (zh) | 2012-10-31 |
| PL2454266T3 (pl) | 2014-01-31 |
| HRP20130941T1 (hr) | 2013-11-08 |
| CA2768210A1 (en) | 2011-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0916286B8 (pt) | amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica | |
| BR112013010519A2 (pt) | composição de higiene oral compreendendo arginina e carbonato de cálcio | |
| BR112013029240A2 (pt) | derivados deuterados do ivacaftor | |
| BR112013032974A2 (pt) | "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas". | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| BRPI1009637A2 (pt) | composto, composição e uso de um composto | |
| BRPI0908353B8 (pt) | composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica | |
| BR112012008889A2 (pt) | compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes | |
| IN2014CN00562A (pt) | ||
| UY32062A (es) | Inhibidores de beta-secretasa | |
| UA108219C2 (uk) | Протипаразитарні дигідроазолові сполуки та композиція, яка їх містить (варіанти) | |
| EP2415749A4 (en) | NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE | |
| BR112015016325A2 (pt) | Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo | |
| UY29469A1 (es) | Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos. | |
| MX2009005413A (es) | Formas cristalinas del acido zoledronico. | |
| BR112015001502A2 (pt) | derivados de tipo azaindazol ou diazaindazol para tratamento de dor | |
| BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer | |
| BR112012012903A2 (pt) | compostos de espiropiperidina | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| MX2013002948A (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. | |
| BR112013022213A2 (pt) | administração parenteral de tapentadol | |
| MX2009007265A (es) | Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion. | |
| BR112012000750A8 (pt) | Sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo | |
| EA201391026A1 (ru) | Кристаллическое производное оксазина и его применение в качестве ингибитора bace | |
| BR112015026840A2 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25C | Requirement related to requested transfer of rights |
Owner name: S*BIO PTE LTDA (SG) |
|
| B25A | Requested transfer of rights approved |
Owner name: CELL THERAPEUTICS, INC. (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: CTI BIOPHARMA CORP. (US) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/07/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |